

ImmunoGen, Inc. Named One of The Boston Globe's 2011 Top Places to Work

WALTHAM, Mass., Nov. 7, 2011 (GLOBE NEWSWIRE) -- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it has been named one of *The Boston Globe's* 2011 Top Places to Work.

The Boston Globe engaged WorkplaceDynamics, specialists in employee engagement and retention, to conduct the survey. Completed surveys were received from over 73,800 individuals across 237 organizations in Massachusetts. Each was asked to grade their organization's performance according to 24 distinct statements, ranging from "new ideas are encouraged at this company" to "it's easy to tell my boss the truth." In addition, all the employers were invited to complete a 12-question survey on workplace practices. To compile the ranking, each employer was measured according to six factors: direction, execution, managers, career, conditions, and pay and benefits.

"This recognition is a great opportunity to highlight the culture we have at ImmunoGen," commented Daniel Junius, President and CEO. "We hire quality people to do important work in a supportive environment, and this commitment makes a real difference as we develop novel anticancer therapies to change the lives of people with cancer. I believe ImmunoGen is a great Company because of our dedicated and innovative employees."

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

CONTACT: For Investors:

Carol Hausner

Executive Director, Investor Relations and

Corporate Communications

ImmunoGen, Inc.

(781) 895-0600

info@immunogen.com

For Media:

Barbara Yates

The Yates Network

(781) 258-6153